Wednesday, July 8, 2026

pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS

Arcus Biosciences

Arcus Biosciences is a pharma organization headquartered in Hayward, USA. It trades on NYSE under ticker RCUS. Primary therapeutic focus areas include Advanced Cancer, Non-small Cell Lung Cancer, Metastatic Clear Cell Re

3928 Point Eden Way, Hayward, California 94545, US HQ
2015 Founded
655 Employees
Public company Type
RCUS · NYSE Ticker
Company details
Status
Public
HQ
3928 Point Eden Way, Hayward, California 94545, US
Founded
2015
Employees
655
Programs
53
Drugs
25
Patents
30
Clinical program

Etrumadenant

Phase 1 · small molecule · Non-small Cell Lung Cancer

Etrumadenant for Non-small Cell Lung Cancer is a Phase 1 program (small_molecule) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).

← All Arcus Biosciences projects Phase 1 small molecule completed

Internal code ARC-5 (AB928CSP0005)

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Arcus Biosciences
Phase
Phase 1
Modality
small_molecule
Indication
Non-small Cell Lung Cancer
Status
completed
Trials
1

Clinical trials